MedWatch warns of alcohol use while on Avinza extended release morphine

Posted by Kate Murphy on November 5th, 2005

The FDA and Ligard Pharmaceuticals notified health professionals and consumers of [label changes for Avinza™](http://www.fda.gov/medwatch/safety/2005/safety05.htm#Avinza) on November 3, 2005. Avinza™ is an extended release form of morphine sulfate provided in capsules. Alcohol can cause a potentially fatal overdose of the drug. FDA MedWatch said,

“Ligand Pharmaceuticals Inc. and FDA notified healthcare professionals of revisions to BOXED WARNING, WARNINGS, PRECAUTIONS, CLINICAL PHARMACOLOGY, and DOSAGE AND ADMINISTRATION sections of the prescribing information to highlight and strengthen the warning that patients should not consume alcohol while taking Avinza. Additionally, patients must not use prescription or non-prescription medications containing alcohol while on Avinza therapy.

Ligard Pharmaceuticals, manufactures of Avinza™ issued a [Dear Health Professional Letter](http://www.fda.gov/medwatch/safety/2005/Avinza-ltr.pdf) to let them know of changes in the labeling. Included in that letter was the following addition to the *Black Box Warning* on the Avinza™ label.

Patients must not consume alcoholic beverages while on AVINZA therapy.
Additionally, patients must not use prescription or non-prescription medications
containing alcohol while on AVINZA therapy. Consumption of alcohol while taking
AVINZA may result in the rapid release and absorption of a potentially fatal dose of morphine.

The [new Avinza label](http://www.fda.gov/medwatch/safety/2005/avinza_PI.pdf) with changes highlighted in yellow can be downloaded as a PDF.

Leave a Comment Comments RSS

Your comments are welcome. However, specific medical advice will not be provided, and we urge you to consult with a qualified physician for diagnosis and for answers to your personal questions.

C3 is not responsible for the medical accuracy of any comments left by persons other than C3 staff members. C3 staff members monitor comments and may respond where appropriate.

For the best response to your colorectal cancer treatment questions, please call our Answer Line at 1-877-4CRC-111 (1-877-427-2111).

Search C3

Sign Our Petition

Guarantee access to colorectal cancer screening for all Americans who need it.

Get Involved

Subscribe to the C3 website

Get C3 news & updates

Get the latest articles in your email inbox or news reader as soon as they are published.

Subscribe